Ghost Tree Capital, LLC
- SEC CIK
- 0001595851
- Latest filing
- Nov 14, 2024
Holdings in Q2 2022
Holdings as of Jun 30, 2022, filed Aug 15, 2022. Long positions only; changes compare share counts with Q1 2022.
- Positions
- 29
- −10 vs. Q1 2022
- Portfolio value
- $145.5M
- −$56.4M (−27.9%) vs. Q1 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| FOLDAmicus Therapeutics, Inc. | COM | 1,000,000 | $10.7M | 7.4% | −100,000−9.1% | Reduced | History |
| APLSApellis Pharmaceuticals, Inc. | COM | 225,000 | $10.2M | 7.0% | −25,000−10.0% | Reduced | History |
| SRPTSarepta Therapeutics, Inc. | COM | 130,000 | $9.74M | 6.7% | +80,000+160.0% | Added | History |
| AXSMAxsome Therapeutics, Inc. | COM | 225,000 | $8.62M | 5.9% | +130,500+138.1% | Added | History |
| COGTCogent Biosciences, Inc. | COM | 900,000 | $8.12M | 5.6% | −800,000−47.1% | Reduced | History |
| HZNPHorizon Therapeutics Public Ltd Co | SHS | 100,000 | $7.98M | 5.5% | +100,000 | New | History |
| MRTXMirati Therapeutics, Inc. | COM | 110,000 | $7.38M | 5.1% | +90,000+450.0% | Added | History |
| PCVXVaxcyte, Inc. | COM | 325,000 | $7.07M | 4.9% | +25,000+8.3% | Added | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 75,000 | $6.97M | 4.8% | −65,000−46.4% | Reduced | History |
| VRDNViridian Therapeutics, Inc. | COM | 600,000 | $6.94M | 4.8% | +133,597+28.6% | Added | History |
| SGENSeagen Inc. | COM | 35,000 | $6.19M | 4.3% | +35,000 | New | History |
| KRTXKaruna Therapeutics, Inc. | COM | 45,000 | $5.69M | 3.9% | −15,000−25.0% | Reduced | History |
| MRUSMerus N.V. | COM | 250,000 | $5.66M | 3.9% | −150,000−37.5% | Reduced | History |
| ISEEIVERIC bio, Inc. | COM | 500,000 | $4.81M | 3.3% | +50,000+11.1% | Added | History |
| CTICCti Biopharma Corp | COM | 800,000 | $4.78M | 3.3% | −500,000−38.5% | Reduced | History |
| RLMDRelmada Therapeutics, Inc. | COM | 250,000 | $4.75M | 3.3% | +150,000+150.0% | Added | History |
| ARVNArvinas, Inc. | COM | 110,000 | $4.63M | 3.2% | 00.0% | Unchanged | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 225,000 | $4.33M | 3.0% | 00.0% | Unchanged | History |
| DSGNDesign Therapeutics, Inc. | COM | 275,000 | $3.85M | 2.6% | +75,000+37.5% | Added | History |
| KZRKezar Life Sciences, Inc. | COM | 450,000 | $3.72M | 2.6% | +50,000+12.5% | Added | History |
| BCRXBiocryst Pharmaceuticals Inc | COM | 325,000 | $3.44M | 2.4% | −25,000−7.1% | Reduced | History |
| RAPTRAPT Therapeutics, Inc. | COM | 165,000 | $3.01M | 2.1% | −85,000−34.0% | Reduced | History |
| WHWKWhitehawk Therapeutics, Inc. | COM | 150,000 | $1.85M | 1.3% | 00.0% | Unchanged | History |
| TARSTarsus Pharmaceuticals, Inc. | COM | 120,000 | $1.75M | 1.2% | 00.0% | Unchanged | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 300,000 | $1.57M | 1.1% | +300,000 | New | History |
| NMTR9 Meters Biopharma, Inc. | COM | 1,800,000 | $469.0K | 0.3% | −1,450,000−44.6% | Reduced | History |
| SYRESpyre Therapeutics, Inc. | COM | 925,000 | $467.0K | 0.3% | +238,401+34.7% | Added | History |
| DICEDICE Therapeutics, Inc. | COM | 30,000 | $466.0K | 0.3% | +30,000 | New | History |
| ALNYAlnylam Pharmaceuticals, Inc. | COM | 1,900 | $277.0K | 0.2% | +1,900 | New | History |
Options (3)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
Sold out since Q1 2022 (15)
Positions held at the end of Q1 2022 that are gone from this filing.
| Security | Class | Shares in Q1 2022 | Value in Q1 2022 | % of portfolio in Q1 2022 | History |
|---|---|---|---|---|---|
| SRRASierra Oncology, Inc. | COM NEW | 325,000 | $10.4M | 5.2% | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 300,000 | $10.2M | 5.1% | History |
| BCYCBicycle Therapeutics PLC | SPONSORED ADS | 100,000 | $4.39M | 2.2% | History |
| VRNAVerona Pharma plc | SPONSORED ADS | 750,000 | $3.74M | 1.9% | History |
| ZNTLZentalis Pharmaceuticals, Inc. | COM | 80,000 | $3.69M | 1.8% | History |
| RCKTRocket Pharmaceuticals, Inc. | COM | 200,000 | $3.17M | 1.6% | History |
| XENEXenon Pharmaceuticals Inc. | COM | 100,000 | $3.06M | 1.5% | History |
| ACRSAclaris Therapeutics, Inc. | COM | 125,000 | $2.15M | 1.1% | History |
| CRNXCrinetics Pharmaceuticals, Inc. | COM | 85,000 | $1.87M | 0.9% | History |
| STSASatsuma Pharmaceuticals, Inc. | COM | 473,562 | $1.80M | 0.9% | History |
| CYPHCypherpunk Technologies Inc. | COM | 993,714 | $1.74M | 0.9% | History |
| VTGNVistagen Therapeutics, Inc. | COM NEW | 1,315,154 | $1.63M | 0.8% | History |
| PRDSPardes Biosciences, Inc. | COM | 85,000 | $614.0K | 0.3% | History |
| LRMRLarimar Therapeutics, Inc. | COM | 100,000 | $405.0K | 0.2% | History |
| PYXSPyxis Oncology, Inc. | COMMON STOCK | 75,000 | $303.0K | 0.2% | History |